Updated Articles for Listserv
Medicare Updated Articles Display Page
| Article ID | Modified By | Modified On | Title |
|---|---|---|---|
| 30395511 | James Marko | 2026-09-24 12:07:24.513 | Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R3 - Effective October 1, 2026 |
| 30395358 | James Marko | 2026-09-24 11:58:37.108 | Billing and Coding: MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis (A60217) - R1 - Effective October 1, 2026 |
| 30395716 | James Marko | 2026-09-24 13:21:02.841 | Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R14 - Effective October 1, 2026 |
| 30391840 | James Marko | 2026-09-23 14:01:04.755 | Avoid Common CMS 2540-24 Cost Report Errors |
| 30395631 | James Marko | 2026-09-24 13:15:12.57 | Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R10 - Effective May 17, 2020 |
| 30395494 | James Marko | 2026-09-24 12:07:22.7 | Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R3 - Effective October 1, 2026 |
| 30395579 | James Marko | 2026-09-24 12:11:20.254 | Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R3 - Effective October 1, 2026 |
| 30392290 | James Marko | 2026-09-24 11:54:23.918 | Billing and Coding: MolDX: BCR-ABL (A55595) - R3 - Effective September 24, 2026 |
| 30395375 | James Marko | 2026-09-24 11:58:38.383 | Billing and Coding: MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis (A60217) - R1 - Effective October 1, 2026 |
| 30395443 | James Marko | 2026-09-24 12:03:05.206 | Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R9 - Effective October 1, 2026 |
| 30395648 | James Marko | 2026-09-24 13:15:13.889 | Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R10 - Effective May 17, 2020 |
| 30395562 | James Marko | 2026-09-24 12:11:18.64 | Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R3 - Effective October 1, 2026 |
| 30395699 | James Marko | 2026-09-24 13:21:01.61 | Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R14 - Effective October 1, 2026 |
| 30395307 | James Marko | 2026-09-24 11:54:25.139 | Billing and Coding: MolDX: BCR-ABL (A55595) - R3 - Effective September 24, 2026 |
| 30395426 | James Marko | 2026-09-24 12:03:03.522 | Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R9 - Effective October 1, 2026 |
| Article ID | Modified By | Modified On | Title |
|---|---|---|---|
| 30392151 | James Marko | 2026-09-23 18:51:12.304 | Required List for Face-to-Face Encounter (F2F) and Written Order Prior to Delivery (WOPD) Update Effective October 28, 2026 |
| 30392037 | Kirby Schwartzbauer | 2026-09-23 15:32:27.182 | Don't Get Caught Off Guard: CMS Expands Authorization Requirements for 2026 |
| 30392074 | James Marko | 2026-09-23 15:34:21.653 | Therapeutic Shoes for Persons with Diabetes (TSPD) Self-Paced Tutorials |
| 30391744 | Kirby Schwartzbauer | 2026-09-22 17:53:29.675 | Enteral Nutrition Billing Basics: Understanding Units of Service and Date Span Requirements |
| 30387062 | James Marko | 2026-09-18 15:06:29.998 | Wheelchair Updates Effective October 28, 2026 |
| Article ID | Modified By | Modified On | Title |
|---|---|---|---|
| 30395341 | James Marko | 2026-09-24 11:58:36.02 | Billing and Coding: MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis (A60217) - R1 - Effective October 1, 2026 |
| 30395682 | James Marko | 2026-09-24 13:21:00.135 | Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R14 - Effective October 1, 2026 |
| 30391857 | James Marko | 2026-09-23 14:01:06.088 | Avoid Common CMS 2540-24 Cost Report Errors |
| 30392256 | James Marko | 2026-09-24 11:54:21.72 | Billing and Coding: MolDX: BCR-ABL (A55595) - R3 - Effective September 24, 2026 |
| 30395528 | James Marko | 2026-09-24 12:11:15.781 | Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R3 - Effective October 1, 2026 |
| 30395460 | James Marko | 2026-09-24 12:07:19.143 | Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R3 - Effective October 1, 2026 |
| 30395409 | James Marko | 2026-09-24 12:03:01.827 | Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R9 - Effective October 1, 2026 |
| 30395324 | James Marko | 2026-09-24 11:58:34.462 | Billing and Coding: MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis (A60217) - R1 - Effective October 1, 2026 |
| 30395597 | James Marko | 2026-09-24 13:15:09.78 | Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R10 - Effective May 17, 2020 |
| 30395392 | James Marko | 2026-09-24 12:02:59.921 | Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R9 - Effective October 1, 2026 |
| 30395614 | James Marko | 2026-09-24 13:15:11.13 | Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R10 - Effective May 17, 2020 |
| 30395545 | James Marko | 2026-09-24 12:11:17.175 | Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R3 - Effective October 1, 2026 |
| 30395477 | James Marko | 2026-09-24 12:07:20.781 | Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R3 - Effective October 1, 2026 |
| 30395665 | James Marko | 2026-09-24 13:20:58.896 | Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R14 - Effective October 1, 2026 |
| 30392273 | James Marko | 2026-09-24 11:54:22.723 | Billing and Coding: MolDX: BCR-ABL (A55595) - R3 - Effective September 24, 2026 |
| Article ID | Modified By | Modified On | Title |
|---|---|---|---|
| 30391732 | Kirby Schwartzbauer | 2026-09-22 17:53:19.48 | Enteral Nutrition Billing Basics: Understanding Units of Service and Date Span Requirements |
| 30392128 | James Marko | 2026-09-23 18:51:11.181 | Required List for Face-to-Face Encounter (F2F) and Written Order Prior to Delivery (WOPD) Update Effective October 28, 2026 |
| 30387079 | James Marko | 2026-09-18 15:06:27.328 | Wheelchair Updates Effective October 28, 2026 |
| 30392025 | Kirby Schwartzbauer | 2026-09-23 15:32:23.92 | Don't Get Caught Off Guard: CMS Expands Authorization Requirements for 2026 |
| 30392057 | James Marko | 2026-09-23 15:34:20.519 | Therapeutic Shoes for Persons with Diabetes (TSPD) Self-Paced Tutorials |